BlackBerry CEO May Consider Exiting Handset Business; Celgene Corporation Favored over Natco in Pre-trial


Follow this company

Companies Mentioned

NYSE:MRK / NASDAQ:FOXA / NASDAQ:CELG / NASDAQ:BBRY
04/10/2014 [ACCESSWIRE]

Merck & Co. Inc. (NYSE: MRK) – For an in-depth report on Merck & Co. Inc. follow: www.BullTrends.com/stockquote/MRK 

Shares of Merck & Co. closed up 3.74% on Wednesday with about 16 million shares traded. The stock was one of the most active stocks on the NYSE and came just 50 cents shy of its yearly high. The company’s biopharmaceutical division, Merck Serono, has commenced a phase III study, START2, on oncology candidate, tecemotide (L-BLP25). Merck KGaA had in-licensed worldwide exclusive rights to tecemotide from Oncothyreon.

Twenty-First Century Fox, Inc. (NASDAQ: FOXA) - For an in-depth report on Twenty-First Century Fox, Inc. follow: www.BullTrends.com/stockquote/FOXA

Shares of FOXA closed up 2.35% on about 15.5 million shares traded on Wednesday. The company had no significant news but was one of the most active stocks on the NASDAQ with a trading range of 32.29 - 33.17 that day.

Celgene Corporation (NASDAQ: CELG) - For an in-depth report on Celgene Corporation follow: www.BullTrends.com/stockquote/CELG 

Shares of CELG closed up 6.58% on nearly 6 million shares traded. The stock was one of the biggest gainers on the NASDAQ. Public documents for the pre-trial Markman hearing appear to favor the company over Natco, the generic drugmaker challenging some of Celgene's Revlimid patents. This is according to the Street's Adam Feuerstein reports.

BlackBerry Limited (NASDAQ: BBRY) – For an in-depth report on BlackBerry Limited follow: www.BullTrends.com/stockquote/BBRY 

BlackBerry shares were little changed on Wednesday; however the company announced that it would consider exiting its handset business if it remains unprofitable. The company’s chief executive officer said this on Wednesday, as the technology company looks to expand its corporate reach with investments, acquisitions and partnerships.

 

Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures. 

COMMENTS

Leave a comment...
 * 

Your Name
 *